Exjade Approval History

• FDA approved: Yes (First approved November 2nd, 2005)
• Brand name: Exjade
• Generic name: deferasirox
• Company: Novartis
• Treatment for: Hemosiderosis, Hemochromatosis

Exjade (deferasirox) is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.

FDA Approval History for Exjade

Date	Article
Jan 23, 2013	FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder
Nov  2, 2005	Exjade Novartis - Treatment for Chronic Iron Overload Due to Blood Transfusions
Sep 29, 2005	FDA Advisory Committee Votes Unanimously to Recommend Approval of Exjade for Once-Daily Oral Treatment of Chronic Iron Overload Due to Blood Transfusions
Jun 22, 2005	FDA Grants Priority Review for Exjade for the Treatment of Chronic Iron Overload Due to Blood Transfusions
May  3, 2005	Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions

See also...

Exjade (deferasirox) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.